<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112797</url>
  </required_header>
  <id_info>
    <org_study_id>ROX-ALE-2018-02</org_study_id>
    <nct_id>NCT04112797</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Treatment With A&quot;LLERGOVAC® HIMENÓPTEROS&quot; in Patients Sensitized to This Venom</brief_title>
  <acronym>HIPNOS</acronym>
  <official_title>Prospective Observational Study to Evaluate the Safety of Treatment With A&quot;LLERGOVAC® HIMENÓPTEROS&quot; in Patients Sensitized to This Venom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a safety and tolerability study of Allergovac Himenopteros in patients sensitized to
      Apis mellifera, Polistes Dominula or Vespula spp. To get this aim all adverse reactions will
      be recorded through the study. In addition, it will be evaluated the treatment efficacy with
      the re-sting after a year of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by WAO classification</measure>
    <time_frame>During 1 year</time_frame>
    <description>All adverse events ocurred during the study Will be collected and clasified following the WAO recommendations. The percentages Will be exposed by number of patients and by dose administrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of vaccine evaluating re-sting test</measure>
    <time_frame>Result of the re-sting test</time_frame>
    <description>Grade of treatment protection after controlled sting</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergy to Himenoptera Venom</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac himenoptera</intervention_name>
    <description>Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People with allergy to himenoptera venom.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients over 14 years of age with allergy to bee venom, Polistes or Vespula. To
             meet this criteria, patients must present a systemic reaction with the bite of one of
             these insects, plus specific IgE detection in the skin test and / or IgE against the
             himenoptera venom.

             2. Prescription treatment with Hymenoptera venom must be indicated and patients are
             susceptible to receive Allergovac® Hymenoptera, according to usual clinical practice.

             3. Patients who have given their written consent. In the case of minors, the assent
             will always be signed by the parent / legal guardian, in addition to the minor.

        Exclusion Criteria:

          1. Patients who have received treatment with Allergovac® Hymenoptera prior to inclusion
             in the study.

          2. Patients under treatment with immunotherapy against aeroallergens.

          3. Patients who have received previous treatment with immunotherapy, with any of the
             venoms that they are going to receive, in the 5 years prior to the inclusion in the
             study.

          4. Patients who under investigator opinion may present difficulties that prevent the
             comprehension of what was written in the information sheet for the patient, the
             informed consent or the completion of self-administered questionnaires.

          5. Patients who are participating in another clinical trial or observational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María Cruz Gómez, MP</last_name>
    <phone>+34 944438000</phone>
    <email>maricruz.gomez@roxall.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leire Begoña</last_name>
    <phone>+34 944438000</phone>
    <email>leire.begona@roxall.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Vega Baja Orihuela</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Ferrer</last_name>
      <email>angelyferrer@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Mexoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36313</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Arenas, MP</last_name>
      <email>luisarenas.alergia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>lluis Marqués, MP</last_name>
      <email>lmarques@gss.scs.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaspar Dalmau, MP</last_name>
      <email>gdalmau.hj23.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Hernández, MP</last_name>
      <email>hernandez_dol@gva.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

